Market closed
Stoke Therapeutics/$STOK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Ticker
$STOK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
128
Website
STOK Metrics
BasicAdvanced
$341M
-
-$1.65
0.98
-
Price and volume
Market cap
$341M
Beta
0.98
52-week high
$17.58
52-week low
$6.00
Average daily volume
858K
Financial strength
Current ratio
5.811
Quick ratio
5.432
Long term debt to equity
1.071
Total debt to equity
2.085
Management effectiveness
Return on assets (TTM)
-25.35%
Return on equity (TTM)
-45.80%
Valuation
Price to revenue (TTM)
9.308
Price to book
1.49
Price to tangible book (TTM)
1.49
Price to free cash flow (TTM)
-3.909
Growth
Revenue change (TTM)
316.34%
Earnings per share change (TTM)
-30.77%
3-year earnings per share growth (CAGR)
-10.98%
What the Analysts think about STOK
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.
STOK Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
STOK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
STOK News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Stoke Therapeutics stock?
Stoke Therapeutics (STOK) has a market cap of $341M as of April 05, 2025.
What is the P/E ratio for Stoke Therapeutics stock?
The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 0 as of April 05, 2025.
Does Stoke Therapeutics stock pay dividends?
No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Stoke Therapeutics dividend payment date?
Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.
What is the beta indicator for Stoke Therapeutics?
Stoke Therapeutics (STOK) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.